Prevention of progression from the earliest stages of the disease is an important unmet need in Multiple Sclerosis (MS). In this study we will focus on a comprehensive assessment of subclinical deficits in patients without clear evidence of neurological dysfunction. Applying personalised interventions targeted to the patient’s deficits may reduce the burden of these deficits, improve the patient’s quality of life and possibly reduce the chance of future, clinically evident, disability accrual. The aim of this pilot study is to assess the subclinical burden of neurological impairments in early Relapsing-Remitting MS patients with no evident neurological disability by applying a comprehensive evaluation, including comorbidities, lifestyle, imaging data, neuropsychological evaluation, gait and balance analyses. From these analyses, we will obtain a risk score for disability worsening over the short-term (1 year). We will then evaluate in a validation cohort the reduction of the rate of patients with evidence of disease activity using a comprehensive and personalised approach (lifestyle counselling, advanced motor and cognitive rehabilitation). As an added value, we will take into account patient preferences and values to support tailoring the interventions.